About LUMICKS
LUMICKS is a company based in Amsterdam (Netherlands) founded in 2014 by Andrea Candelli. LUMICKS has raised $93.38 million across 10 funding rounds from investors including T. Rowe Price, European Investment Bank and Farallon Capital Management. LUMICKS offers products and services including Cell Avidity, Dynamic Single-Molecule, Avidion, C-Trap, and z-Movi. LUMICKS operates in a competitive market with competitors including 10X Genomics, Mission Bio, Cellares, LevitasBio and Rebus Biosystems, among others.
- Headquarter Amsterdam, Netherlands
- Founders Andrea Candelli
- SectorsHealthcareTechnology
- Email••••••••
- Phone•••• ••••
- Website lumicks.com
- Social LinkedIn X Facebook
- Total Equity Funding$93.38M (USD)
in 10 rounds
- Latest Funding Round$21.87M (USD), Debt – Venture
Oct 2024
- InvestorsT. Rowe Price
& 10 more
Products & Services of LUMICKS
LUMICKS offers a comprehensive portfolio of products and services, including Cell Avidity, Dynamic Single-Molecule, Avidion, C-Trap, and z-Movi.
Measures binding strength in cellular contexts for research applications.
Visualizes and analyzes molecular mechanisms in real-time.
Enables next-generation cell avidity analysis for studies.
Reimagines interactions through single-molecule manipulation.
Supports small-scale cell avidity studies effectively.
Offers white-glove support for cell avidity experiments.
Funding Insights of LUMICKS
LUMICKS has successfully raised a total of $93.38M across 10 strategic funding rounds. The most recent funding activity was a Debt – Venture round of $21.87 million completed in October 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $93.38M
- Total Rounds 10
- Last Round Debt – Venture — $21.87M
- First Round $1.02M
(Jun 2015)
- Investors Count 11
All 10 funding rounds of LUMICKS with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2024 | $21.87M | Debt – Venture | – | – | |
| Jan 2023 | $294,304 | Grant | – | – | |
| Sep 2022 | $48,656 | Grant | – | – | |
| Apr 2021 | $93.38M | Series D | – | Farallon Capital Management, Lauxera Capital Partners | |
| Oct 2020 | $2.36M | Grant | – | – | |
| Oct 2019 | $304,964 | Grant | – | – | |
| May 2019 | $112,004 | Grant | – | – | |
| Sep 2017 | $99,336 | Grant | – | – | |
| Jan 2017 | $88,669 | Grant | – | – | |
| Jun 2015 | $1.02M | Grant | – | – |
11 investors in total: 11 institutional.
Investors in LUMICKS
LUMICKS has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include T. Rowe Price, European Investment Bank and Farallon Capital Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Finance and advisory services for infrastructure projects are provided. | 1958 | eib.org | Luxembourg, Luxembourg | |
Government agency and accelerator focusing on innovative startups and SMEs | – | eicfund.eu | Brussels, Belgium | |
Multiple investment strategies are pursued by this hedge fund. | 1986 | faralloncapital.com | San Francisco, United States | |
Venture capital firm focused on the healthcare sector | – | lauxera.com | Paris, France | |
Investment management services are provided focusing on healthcare innovation. | – | puravidainvestments.com | New York, United States | |
Early-stage startups are invested in by sector-agnostic VC fund. | – | irvinginvestors.com | New York, United States | |
Private equity and venture captial firm focused on healthcare sectors | – | gildehealthcare.com | Cambridge, United States | |
Venture capital investments in technology and startups. | 2016 | visionfund.com | London, United Kingdom | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
- | – | parianglobal.com | - |
Investor details for LUMICKS
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of LUMICKS
45 people are tracked at LUMICKS (9 in leadership, 10 in board & advisors, 26 in team).
| Name | Role | Group |
|---|---|---|
Andrea Candelli | Co-Founder | Leadership |
Gijs Oude Elberink | COO | Leadership |
Freek Blom | RD Director | Leadership |
Timo Peters | Study Director | Leadership |
Michael Savage | Director Corporate Business Development | Leadership |
Gerrit Sitters | General Manager CA | Leadership |
Hannah van Drunen | HR Director | Leadership |
Divan de Clercq | Human Resources Business Partner | Leadership |
Qing Wang | Business Director APR | Leadership |
Solange Glaize | Director | Board & advisors |
Pieter Van Der Meer | Director | Board & advisors |
Alex Slack | Director | Board & advisors |
Melissa McLaughlin | Director | Board & advisors |
Peter Van Den Broek | Director | Board & advisors |
Don Kania | Chair | Board & advisors |
Gija Wuife | Advisor | Board & advisors |
Gigi Wang | Advisor | Board & advisors |
Erwin Peterman | Advisor | Board & advisors |
John Rediske | Advisor | Board & advisors |
Felix Oswald | Research And Development Team Manager | Team |
25 more people are available in the full profile.
Complete people profiles for LUMICKS
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of LUMICKS
3 dated milestones of LUMICKS across 10 years, from founding to its latest funding, stage changes and deals.
- Founded LUMICKS is founded.
- Funding First funding round of $1.0M.
- Funding Latest funding round, Debt – Venture, of $21.9M.
Competitors of LUMICKS
LUMICKS operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as 10X Genomics, Mission Bio, Cellares, LevitasBio and Rebus Biosystems, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| 10xgenomics.com | 2012 | Pleasanton, United States | $199.9M | 961 | Instrument systems for genomic research and sequencing libraries are developed. | |
| missionbio.com | 2014 | San Francisco, United States | $110M | 109 | Single-cell multi-omics platform is provided for genotypic and phenotypic analysis. | |
| cellares.com | 2019 | San Francisco, United States | $355M | – | Medical devices for cell-based therapy manufacturing are produced. | |
| levitasbio.com | 2017 | San Francisco, United States | $73.77M | – | Single-cell imaging platform developed via magnetic levitation technology. | |
| rebusbio.com | 2006 | Santa Clara, United States | $20M | – | An imaging system for single-cell gene analysis is developed. | |
| atrandi.com | 2016 | Vilnius, Lithuania | $31.01M | – | Microfluidic solutions for life sciences and single-cell analysis are developed. | |
| xcellbio.com | 2012 | San Francisco, United States | $40.9M | 11 | Cell culture analysis devices for cancer research are developed. | |
| biolog.com | 1984 | Hayward, United States | $33.62M | 27 | Cell-based phenotyping technologies and assays are provided for microbial analysis. |
Detailed competitors of LUMICKS
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of LUMICKS
The website of LUMICKS (lumicks.com) receives about 12.7K visits a month.
- Monthly visits12.7K
▼ 7.7% vs previous month
Websites whose visitors overlap most with LUMICKS. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| youtube.com | 100% | 30.4B | #2 | View details |
Latest news on Lumicks
Complete news archive for LUMICKS
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to LUMICKS
10 companies that operate in the same segment as LUMICKS (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about LUMICKS
LUMICKS was founded in 2014 and raised its 1st funding round 1 year after it was founded.
LUMICKS is headquartered in Amsterdam, Netherlands.
LUMICKS is a funded company, having raised a total of $93.38M across 10 funding rounds to date. The company's 1st funding round was a Grant of $1.02M, raised on Jun 2015.
Manufacturer of optical tweezers for single-molecule analysis instruments. The product portfolio of the company includes C-Trap, an integrated system with optical tweezers, a confocal microscope, and a microfluidic system to analyze protein folding, DNA repair, DNA organization, Protein polymer, and filaments. Its product, AFS-acoustic force spectroscopy (a single molecule manipulation system), and u-Flux (an integrated microfluidic system) are used in performing experiments in a laminar flow environment.
LUMICKS's top competitors include 10X Genomics, Mission Bio and Cellares.
LUMICKS offers Cell Avidity, Dynamic Single-Molecule, Avidion, C-Trap, and 2 more products and services.
LUMICKS has 11 investors. Key investors include T. Rowe Price, European Investment Bank, Farallon Capital Management, European Union, and SoftBank Vision Fund.